Vitamin B12 Cobalamin

What the laboratory says this test is for

This panel is designed to evaluate a patient for the presence of potentially reversible (i.e., secondary) causes of dementia such as Vitamin B12 deficiency, hypothyroidism, hypoparathyroidism, anemia, hypoxia or hypercapnia, hepatic and renal encephalopathies, diabetes and dehydration.The panel includes a Complete Blood Count, TSH, Vitamin B12, Folate and a Comprehensive Metabolic Panel. It is modeled after the recommendations of the American Academy of Neurology (AAN), a National Institutes of Health Consensus Panel, the European Federation of Neurological Societies (EFNS), and others [1-4].References1. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153. 2. Consensus conference. Differential diagnosis of dementing diseases. JAMA. 1987;258:3411-3416. 3. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159-1179. 4. Simmons BB, Hartmann B, DeJoseph D. Evaluation of suspected dementia. Am Fam Physician. 2011;84:895-902.

What the laboratory says this test is for

About 10-30% of patients continue with lingering symptoms four or more weeks after COVID-19 infection, including those who had mild, or no symptoms termed as post-COVID conditions. The Centers for Disease Control (CDC) provided Interim Guidance for Assessment and Testing for Evaluating and Caring for Patients with Post-COVID Conditions. The CDC recommends laboratory testing be guided by the patient history, physical examination, and clinical findings. A basic panel of laboratory tests might be considered for patients with ongoing symptoms to assess for conditions that may respond to treatment, until more information and evidence is available for specific laboratory testing for post-COVID conditions. This panel is to be considered for persistent symptoms if basic testing such as Complete Blood Counts, Basic Metabolic Profile, and Liver Function Tests has been completed.

What the laboratory says this test is for

About 10-30% of patients continue with lingering symptoms four or more weeks after COVID-19 infection, including those who had mild, or no symptoms termed as post-COVID conditions. The Centers for Disease Control (CDC) provided Interim Guidance for Assessment and Testing for Evaluating and Caring for Patients with Post-COVID Conditions. The CDC recommends laboratory testing be guided by the patient history, physical examination, and clinical findings. A basic panel of laboratory tests might be considered for patients with ongoing symptoms to assess for conditions that may respond to treatment, until more information and evidence is available for specific laboratory testing for post-COVID conditions. This panel is to be considered for basic testing if no previous testing was performed.

What the laboratory says this test is for

This panel is designed to evaluate a patient for the presence of potentially reversible (i.e., secondary) causes of dementia such as Vitamin B12 deficiency, hypothyroidism, hypoparathyroidism, anemia, hypoxia or hypercapnia, hepatic and renal encephalopathies, diabetes, and dehydration.The panel includes a Complete Blood Count, TSH, Vitamin B12, Folate, and a Comprehensive Metabolic Panel. It is modeled after the recommendations of the American Academy of Neurology (AAN), a National Institutes of Health Consensus Panel, the European Federation of Neurological Societies (EFNS), and others [1-4].References 1. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153. 2. Consensus conference. Differential diagnosis of dementing diseases. JAMA. 1987;258:3411-3416. 3. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159-1179. 4. Simmons BB, Hartmann B, DeJoseph D. Evaluation of suspected dementia. Am Fam Physician. 2011;84:895-902.

What the laboratory says this test is for

B12 is decreased in pernicious anemia, total or partial gastrectomy, malabsorption and certain congenital and biochemical disorders.